Investigational drug · Phase 3
HS-20093
Also called: Ris-Rez, Risvutatug rezetecan, GSK5764227
Not approved by FDA. In 16 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neoplasms, Lung, Sarcoma, Osteosarcoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
16
14 still active
All registered trials
27
Any phase or sponsor naming "HS-20093"
First trial start
2023
Jun 8, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-20093", any sponsor or status.
- Phase 115
Conditions studied
As listed on its trial records.
- Neoplasms, Lung
- Sarcoma
- Osteosarcoma
- Non-Small Cell Lung Cancer
- Gastrointestinal Neoplasms
- Head and Neck Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma (ESCC)
- Prostate Cancer
- Lung Neoplasm
- Advanced Solid Tumor
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Stomach and esophageal cancer · Head and neck cancer · Sarcoma · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-20093" as an intervention, largest first.
Hansoh BioMedical R&D CompanyIndustry
NCT06621563 · 780 participants (planned) · Start Dec 14, 2024 · Primary completion Mar 30, 2026
Drug: HS-20117 combined HS-20093; HS-20117 combined Platinum-containing chemotherapy and 4 more · For: Solid Tumors; Non-Small Cell Lung Cancer; Colorectal Cancer
Sites: Tianjin, China
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid TumorsNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06963502 · 762 participants (planned) · Start May 30, 2025 · Primary completion Dec 31, 2028
Drug: HS-10370; HS-20117 and 6 more · For: Advanced Solid Tumors; Colorectal Cancer; Non-Small Cell Lung Cancer
Sites: Hangzhou, China; Shanghai, China
Hansoh BioMedical R&D CompanyIndustry
NCT06332170 · 610 participants (planned) · Start Apr 26, 2024 · Primary completion May 30, 2026
Drug: HS-20093; Adebrelimab and 3 more · For: Advanced Solid Tumor
Sites: Shanghai, China
Hansoh BioMedical R&D CompanyIndustry
NCT06825624 · 560 participants (planned) · Start Oct 3, 2024 · Primary completion Oct 31, 2026
Drug: HS-20093; Bevacizumab and 4 more · For: Metastatic Colorectal Cancer (CRC)
Sites: Hangzhou, China
- A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Pivotal-lookingNot yet recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT07621601 · 494 participants (planned) · Start Jul 31, 2026 · Primary completion Dec 31, 2030
Drug: HS-20093 for Injection; Irinotecan; Paclitaxel; Docetaxel · For: Esophageal Squamous Cell Carcinoma (ESCC)
- ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerPivotal-lookingCompleted
Hansoh BioMedical R&D CompanyIndustry
NCT06498479 · 461 participants · Start Jul 4, 2024 · Primary completion Aug 20, 2026
Drug: HS-20093; Topotecan · For: Small Cell Lung Cancer
Sites: Beijing, China; Harbin, China; Zhengzhou, China · 9 sites in all
- A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsPivotal-lookingNot yet recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT07464327 · 450 participants (planned) · Start Mar 31, 2026 · Primary completion Dec 31, 2028
Drug: HS-20093; Docetaxel · For: Non-Small Cell Lung Cancer
- ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.Not yet recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT06699576 · 448 participants (planned) · Start Dec 20, 2024 · Primary completion Dec 30, 2026
Drug: HS-20093; Anlotinib and 2 more · For: Osteosarcoma; Soft Tissue Sarcoma (STS)
- A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung CancerPivotal-lookingNot yet recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT06526624 · 406 participants (planned) · Start Sep 30, 2024 · Primary completion Nov 30, 2027
Drug: HS-20093 · For: Limited-stage Small-cell Lung Cancer
- A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLCNot yet recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT07892625 · 338 participants (planned) · Start Nov 15, 2026 · Primary completion Sep 15, 2028
Drug: HS-20093 for Injection; ZG006 and 1 more · For: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of risvutatug rezetecan versus gemcitabine-docetaxel in relapsed or refractory osteosarcoma: primary results from the ARTEMIS-011 phase III trial.
Xie L, Yao W, Hua Y, et al. · Ann Oncol 2026
- Preclinical Evaluation of B7-H3-Targeted ADC-Based Molecular Imaging in Lung and Triple-Negative Breast Cancer.
Sui J, Qin J, Hsu JC, et al. · Mol Pharm 2026
- HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial.
Duan J, Sun Y, Wang Q, et al. · Cancer Cell 2026
- B7-H3 Inhibitors in Oncology Clinical Trials: A Review.
Feustel K, Martin J, Falchook GS · J Immunother Precis Oncol 2024
- B7-H3/CD276 and small-cell lung cancer: What's new?
Fabrizio FP, Muscarella LA, Rossi A · Transl Oncol 2024
Also in development for Neoplasms, Lung
- ESG401Phase 33 trials
Qilu Pharmaceutical Co., Ltd. · Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC), Neoplasms, Breast
- JDQ443OpnurasibPhase 23 trials
Novartis · Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation, Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
- TNO155Phase 22 trials
Novartis · Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation, KRAS G12C Mutant Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.